Impact of dapagliflozin on bone mineral metabolism in non-diabetic patients with chronic kidney disease: a randomized, double-blind, placebo-controlled study
This exploratory randomized controlled trial did not demonstrate any meaningful impact of dapagliflozin on either bone turnover or QCT markers. While these findings provide reassuring preliminary evidence, larger studies are needed to definitively establish long-term bone safety of dapagliflozin in non-diabetic patients with CKD.
Authors
- Kareem A. Nabieh
- Huda Refaie
- Muhammed Ahmed Elhadedy (ORCID: https://orcid.org/0000-0002-8735-9416)
- Ahmed E. Abdulgalil (ORCID: https://orcid.org/0000-0001-6516-2404)
- Amr El‐Husseini (ORCID: https://orcid.org/0000-0001-9072-5029)
- Samir Sally
- Mohamed Sobh (ORCID: https://orcid.org/0000-0003-1217-6559)
- Wael I. Mortada (ORCID: https://orcid.org/0000-0001-7797-0302)
- Mohamed Elshayeb
Institutions
- University of Kentucky (US)
- Mansoura University (EG)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1093/ckj/sfaf384
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00